Literature DB >> 25979472

Seq2pathway: an R/Bioconductor package for pathway analysis of next-generation sequencing data.

Bin Wang1, John M Cunningham1, Xinan Holly Yang1.   

Abstract

UNLABELLED: Seq2pathway is an R/Python wrapper for pathway (or functional gene-set) analysis of genomic loci, adapted for advances in genome research. Seq2pathway associates the biological significance of genomic loci with their target transcripts and then summarizes the quantified values on the gene-level into pathway scores. It is designed to isolate systematic disturbances and common biological underpinnings from next-generation sequencing (NGS) data. Seq2pathway offers Bioconductor users enhanced capability in discovering collective pathway effects caused by both coding genes and cis-regulation of non-coding elements.
AVAILABILITY AND IMPLEMENTATION: The package is freely available at http://www.bioconductor.org/packages/release/bioc/html/seq2pathway.html. CONTACT: xyang2@uchicago.edu SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
© The Author 2015. Published by Oxford University Press.

Entities:  

Mesh:

Year:  2015        PMID: 25979472      PMCID: PMC4565027          DOI: 10.1093/bioinformatics/btv289

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


1 Introduction

Functional gene-set analysis (fGSA) improves biological interpretability of genomic features with respect to prior knowledge and has led to important biological discoveries (Khatri ). Its power lies in the fact that it detects statistical significance over an entire dataset of gene-sets and yields biologically meaningful interpretations (Subramanian ). Recently, researchers revealed driver pathways that predispose individuals to disease (Vandin ) and shed light on the development of targeted therapy (Gonzalez-Perez ) by performing fGSA on genes proximal to significantly disease-associated loci. However, with the increasing growth of genomic sequencing measurements, non-coding regulatory loci pose a critical challenge to fGSA, as nearly 99% of the nucleotides in the human genome do not code for proteins but instead richly harbor functional regulators of genes (Kellis ). ‘Gene-based’ fGSA methods neglect non-coding regulatory information because they have no readily annotated gene function and cannot be assigned to a specific biological pathway. For example, HOMER (Hypergeometric Optimization of Motif EnRichment), a popular tool for discovering cis-regulatory regions before any subsequent fGSA, links genomic loci to only the nearest genes (Wang ). Other fGSA algorithms take into account single-nucleotide polymorphisms (SNPs) only located in or near coding genes (Koster ; Nam ) or exonic mutations (Boca ; Gonzalez-Perez ; Leiserson ). ‘Sequence-derived’ fGSA regarding the functional impact of not only coding genes, but also non-coding regulators, is necessary. A growing body of evidence supports the strategy of connecting genomic loci and coding genes using a many-to-many mapping and considering long-distance cis-regulation. First, non-coding regions richly harbor functional regulatory elements in humans (Kellis ; Schierding ). Second, nearly half of the disease-associated SNPs are located in gene deserts (Visel ). Third, our recent study suggests that a disease-associated SNP located in an intron could be the enhancer of a neighboring gene rather than of its host gene (van den Boogaard ). The first sequence-derived fGSA method is GREAT (the Genomic Regions Enrichment of Annotations Tool) (McLean ). GREAT quantifies an fGSA score by determining if the total number of loci within the regulatory domain of genes in a gene-set is greater than expected. The ChIP-Enrich method then empirically adjusts the length of the gene body and its surrounding non-coding sequence (Welch ). However, both GREAT and ChIP-Enrich treat all loci equally, despite the fact that a threshold for significance is always experimentally context-dependent and arbitrary. We propose a new sequence-derived fGSA tool named ‘seq2pathway’ that fills the non-coding region gap in fGSA by considering quantitative sequencing measurements. We initially developed FAIME (Functional Analysis of Individual Microarray/RNAseq Expression) to compare the cumulative quantitative effects of genes inside an ontology (set of functionally related genes) with those outside, thus overcoming a number of difficulties in prior fGSA methods (Yang ). We here provide the community a Bioconductor package that (i) quantifies the functional impact of both coding genes and non-coding loci, (ii) generalizes four fGSA methods, including FAIME, to variable next-generation sequencing (NGS) data and (iii) wraps gene locus definitions for human and mouse genomes from the GENCODE project (Harrow ) into R objects.

2 Main features

Seq2pathway is designed for knowledge discovery using a variety of NGS data (e.g. ChIP-seq, RNA-seq, SNPs, etc) by taking the contribution of non‐coding loci and their experimental significance scores into consideration. Users can apply the ‘seq2pathway’ function jointly, or in a two-step algorithm consisting of ‘seq2gene’ and ‘gene2pathway’ components separately (For workflow see Supplementary Fig. S1). The seq2gene step links both coding and non-coding regions to coding genes in a many-to-many mapping (For detailed Pseudo code see Supplementary Fig. S2) (Yang ). Using seq2gene with a search radius of 100 kb, our recent study in vivo defined a novel cis-regulatory element from both ChIP-seq and transcriptomic data (Hoffmann ). Compared with other methods, seq2gene outputs candidate targets with detailed loci-to-gene mappings (e.g. exon, intron, CDS (CoDing sequence), UTR (UnTranslated Region), promoter and neighbor). This feature allows researchers to understand the function of the region and design creative downstream analyses for the genomic locus hits, an effort only previously achieved by annotation tools HOMER and ChIP-Enrich. The gene2pathway step integrates several cutting-edge fGSA algorithms, characterized by the improved FAIME method (Supplementary Fig. S3). We also provide other three alternative methods: Fisher’s exact test, the Kolmogorov–Smirnov test, and the cumulative rank test (Subramanian ). All of these implemented analyses condense gene-by-sample measurements (gene profiles) to gene-set-by-sample measurements (gene-set profiles), which are gene-coverage-difference tolerable and free of gene-set size preference for gene-sets with five or more genes (Supplementary Figs S4A, S6A, and S8A). Significance of biologically-defined loci of genomic aberrations or functional elements has been lacking of attention than their recurrence. Confidence of threshold-based significance is likely to depend on the choice of genomic background and the test statistic; thus, empirical approaches are recommended (Glaab ). Seq2pathway calculates empirical P-values for each gene-set in a sample by shuffling the gene scores derived from genomic locus hits of this sample to generate gene-set scores from the null hypothesis. This empirical assessment overcomes common biases of gene length in pathway analysis of NGS data (Supplementary Figs S4B and S6B). Additionally, we collapsed significant scores per gene when a gene was mapped to multiple neighboring genomic loci, removing the bias of linkage disequilibrium for the downstream pathway analysis (Supplementary Fig. S6C). Finally, researchers can run seq2pathway against user-supplied gene-sets and the wrapped Gene Ontology (GO). This feature essentially allows unbiased comparisons of methods and results.

3 Case study

To highlight the earlier features, we demonstrate the application of seq2pathway on a variety of different NGS datasets, point out the novel insights obtained only by seq2pathway, and summarize the take home message (Supplementary Document). We first compared seq2pathway with ChIP-Enrich and GREAT to test GO enrichment in a set of H3K27me3 peaks using the same criteria (Supplementary Fig. S5, false discovery rate (FDR) < 0.01, count ≥5 and search radius = 5 kb). Both seq2pathway and GREAT identified the biological process GO:0008285 (negative regulation of cell proliferation), while seq2pathway concentrates better with less identified GO terms than the other two methods. Interestingly, the significance of GO:0003705 (distal enhancer region for RNA polymerase II), a molecular function significantly enriched by bivalent genes marked with both H3K4me3 and H3K27me3 (Li ), was obtained only with seq2pathway (Supplementary Fig. S5B). We next tested 460 human height-associated SNP loci and compared the output with the seq2pathway (setting the parameter SNP = T) to the results of GREAT (Binomial FDR < 0.05, observed regions >3, region fold enrich >2). We applied a search radius = 5 kb for both methods. The valuable biological processes obtained only with seq2pathway include GO:0001701 (in utero embryonic development) that was predicted recently (Fig. 1) in a comprehensive study on human height (Wood ).
Fig. 1.

The identification of biological process from 460 height-associated SNPs. (A) Results of both methods were comparable to the prediction of a comprehensive study on human height (Wood ). (B) A demonstration of the case that both common and different genes are identified by two methods for the same GO term (GO:0006397). (C) Common and different SNPs are identified by two methods for the genes in Panel B. (D) Selective biological process terms identified by two or three methods, followed by the commonly identified (in black) and seq2pathway specifically identified (in blue, underlined) genes and SNPs shown in panels B–C.

The identification of biological process from 460 height-associated SNPs. (A) Results of both methods were comparable to the prediction of a comprehensive study on human height (Wood ). (B) A demonstration of the case that both common and different genes are identified by two methods for the same GO term (GO:0006397). (C) Common and different SNPs are identified by two methods for the genes in Panel B. (D) Selective biological process terms identified by two or three methods, followed by the commonly identified (in black) and seq2pathway specifically identified (in blue, underlined) genes and SNPs shown in panels B–C. When we applied seq2pathway to RNA-seq data, individualized gene-set profiles allow the derivation of statistics at the pathway level directly rather than at the gene level. The advantages of seq2pathway lie in noise and dimension reduction, its desired biological interpretability, as well as a platform for novel integrative systems biology analysis (Yang )

4 Conclusion

It is a breakthrough in genome analytics coordinates to assign region significance scores such as binding affinity estimates from ChIP-Seq onto a uniform gene-set scale. This feature facilitates the integrative analysis of multiple datasets (Yang ). The most critical issue in functionally interpreting genomic loci is to bridge non-coding regions with gene function. Seq2pathway offers the capacity to discover collective pathway effects caused by long-distance cis-regulation of non-coding elements. Importantly, seq2pathway enhances an alternative tool to integrate a number of ‘omics’ datasets into a condensed space of quantitative gene-set scores. This functional level integration will help generate assumptions, constraints, and interpretation in systems biology.
  23 in total

1.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

2.  GSA-SNP: a general approach for gene set analysis of polymorphisms.

Authors:  Dougu Nam; Jin Kim; Seon-Young Kim; Sangsoo Kim
Journal:  Nucleic Acids Res       Date:  2010-05-25       Impact factor: 16.971

3.  ChIP-Enrich: gene set enrichment testing for ChIP-seq data.

Authors:  Ryan P Welch; Chee Lee; Paul M Imbriano; Snehal Patil; Terry E Weymouth; R Alex Smith; Laura J Scott; Maureen A Sartor
Journal:  Nucleic Acids Res       Date:  2014-05-30       Impact factor: 16.971

4.  Human-specific loss of regulatory DNA and the evolution of human-specific traits.

Authors:  Cory Y McLean; Philip L Reno; Alex A Pollen; Abraham I Bassan; Terence D Capellini; Catherine Guenther; Vahan B Indjeian; Xinhong Lim; Douglas B Menke; Bruce T Schaar; Aaron M Wenger; Gill Bejerano; David M Kingsley
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

Review 5.  Ten years of pathway analysis: current approaches and outstanding challenges.

Authors:  Purvesh Khatri; Marina Sirota; Atul J Butte
Journal:  PLoS Comput Biol       Date:  2012-02-23       Impact factor: 4.475

6.  Identification of epigenetic modifications that contribute to pathogenesis in therapy-related AML: Effective integration of genome-wide histone modification with transcriptional profiles.

Authors:  Xinan Holly Yang; Bin Wang; John M Cunningham
Journal:  BMC Med Genomics       Date:  2015-05-29       Impact factor: 3.063

7.  Simultaneous identification of multiple driver pathways in cancer.

Authors:  Mark D M Leiserson; Dima Blokh; Roded Sharan; Benjamin J Raphael
Journal:  PLoS Comput Biol       Date:  2013-05-23       Impact factor: 4.475

8.  BGDB: a database of bivalent genes.

Authors:  Qingyan Li; Shuabin Lian; Zhiming Dai; Qian Xiang; Xianhua Dai
Journal:  Database (Oxford)       Date:  2013-07-26       Impact factor: 3.451

9.  Defining the role of common variation in the genomic and biological architecture of adult human height.

Authors:  Andrew R Wood; Tonu Esko; Jian Yang; Sailaja Vedantam; Tune H Pers; Stefan Gustafsson; Audrey Y Chu; Karol Estrada; Jian'an Luan; Zoltán Kutalik; Najaf Amin; Martin L Buchkovich; Damien C Croteau-Chonka; Felix R Day; Yanan Duan; Tove Fall; Rudolf Fehrmann; Teresa Ferreira; Anne U Jackson; Juha Karjalainen; Ken Sin Lo; Adam E Locke; Reedik Mägi; Evelin Mihailov; Eleonora Porcu; Joshua C Randall; André Scherag; Anna A E Vinkhuyzen; Harm-Jan Westra; Thomas W Winkler; Tsegaselassie Workalemahu; Jing Hua Zhao; Devin Absher; Eva Albrecht; Denise Anderson; Jeffrey Baron; Marian Beekman; Ayse Demirkan; Georg B Ehret; Bjarke Feenstra; Mary F Feitosa; Krista Fischer; Ross M Fraser; Anuj Goel; Jian Gong; Anne E Justice; Stavroula Kanoni; Marcus E Kleber; Kati Kristiansson; Unhee Lim; Vaneet Lotay; Julian C Lui; Massimo Mangino; Irene Mateo Leach; Carolina Medina-Gomez; Michael A Nalls; Dale R Nyholt; Cameron D Palmer; Dorota Pasko; Sonali Pechlivanis; Inga Prokopenko; Janina S Ried; Stephan Ripke; Dmitry Shungin; Alena Stancáková; Rona J Strawbridge; Yun Ju Sung; Toshiko Tanaka; Alexander Teumer; Stella Trompet; Sander W van der Laan; Jessica van Setten; Jana V Van Vliet-Ostaptchouk; Zhaoming Wang; Loïc Yengo; Weihua Zhang; Uzma Afzal; Johan Arnlöv; Gillian M Arscott; Stefania Bandinelli; Amy Barrett; Claire Bellis; Amanda J Bennett; Christian Berne; Matthias Blüher; Jennifer L Bolton; Yvonne Böttcher; Heather A Boyd; Marcel Bruinenberg; Brendan M Buckley; Steven Buyske; Ida H Caspersen; Peter S Chines; Robert Clarke; Simone Claudi-Boehm; Matthew Cooper; E Warwick Daw; Pim A De Jong; Joris Deelen; Graciela Delgado; Josh C Denny; Rosalie Dhonukshe-Rutten; Maria Dimitriou; Alex S F Doney; Marcus Dörr; Niina Eklund; Elodie Eury; Lasse Folkersen; Melissa E Garcia; Frank Geller; Vilmantas Giedraitis; Alan S Go; Harald Grallert; Tanja B Grammer; Jürgen Gräßler; Henrik Grönberg; Lisette C P G M de Groot; Christopher J Groves; Jeffrey Haessler; Per Hall; Toomas Haller; Goran Hallmans; Anke Hannemann; Catharina A Hartman; Maija Hassinen; Caroline Hayward; Nancy L Heard-Costa; Quinta Helmer; Gibran Hemani; Anjali K Henders; Hans L Hillege; Mark A Hlatky; Wolfgang Hoffmann; Per Hoffmann; Oddgeir Holmen; Jeanine J Houwing-Duistermaat; Thomas Illig; Aaron Isaacs; Alan L James; Janina Jeff; Berit Johansen; Åsa Johansson; Jennifer Jolley; Thorhildur Juliusdottir; Juhani Junttila; Abel N Kho; Leena Kinnunen; Norman Klopp; Thomas Kocher; Wolfgang Kratzer; Peter Lichtner; Lars Lind; Jaana Lindström; Stéphane Lobbens; Mattias Lorentzon; Yingchang Lu; Valeriya Lyssenko; Patrik K E Magnusson; Anubha Mahajan; Marc Maillard; Wendy L McArdle; Colin A McKenzie; Stela McLachlan; Paul J McLaren; Cristina Menni; Sigrun Merger; Lili Milani; Alireza Moayyeri; Keri L Monda; Mario A Morken; Gabriele Müller; Martina Müller-Nurasyid; Arthur W Musk; Narisu Narisu; Matthias Nauck; Ilja M Nolte; Markus M Nöthen; Laticia Oozageer; Stefan Pilz; Nigel W Rayner; Frida Renstrom; Neil R Robertson; Lynda M Rose; Ronan Roussel; Serena Sanna; Hubert Scharnagl; Salome Scholtens; Fredrick R Schumacher; Heribert Schunkert; Robert A Scott; Joban Sehmi; Thomas Seufferlein; Jianxin Shi; Karri Silventoinen; Johannes H Smit; Albert Vernon Smith; Joanna Smolonska; Alice V Stanton; Kathleen Stirrups; David J Stott; Heather M Stringham; Johan Sundström; Morris A Swertz; Ann-Christine Syvänen; Bamidele O Tayo; Gudmar Thorleifsson; Jonathan P Tyrer; Suzanne van Dijk; Natasja M van Schoor; Nathalie van der Velde; Diana van Heemst; Floor V A van Oort; Sita H Vermeulen; Niek Verweij; Judith M Vonk; Lindsay L Waite; Melanie Waldenberger; Roman Wennauer; Lynne R Wilkens; Christina Willenborg; Tom Wilsgaard; Mary K Wojczynski; Andrew Wong; Alan F Wright; Qunyuan Zhang; Dominique Arveiler; Stephan J L Bakker; John Beilby; Richard N Bergman; Sven Bergmann; Reiner Biffar; John Blangero; Dorret I Boomsma; Stefan R Bornstein; Pascal Bovet; Paolo Brambilla; Morris J Brown; Harry Campbell; Mark J Caulfield; Aravinda Chakravarti; Rory Collins; Francis S Collins; Dana C Crawford; L Adrienne Cupples; John Danesh; Ulf de Faire; Hester M den Ruijter; Raimund Erbel; Jeanette Erdmann; Johan G Eriksson; Martin Farrall; Ele Ferrannini; Jean Ferrières; Ian Ford; Nita G Forouhi; Terrence Forrester; Ron T Gansevoort; Pablo V Gejman; Christian Gieger; Alain Golay; Omri Gottesman; Vilmundur Gudnason; Ulf Gyllensten; David W Haas; Alistair S Hall; Tamara B Harris; Andrew T Hattersley; Andrew C Heath; Christian Hengstenberg; Andrew A Hicks; Lucia A Hindorff; Aroon D Hingorani; Albert Hofman; G Kees Hovingh; Steve E Humphries; Steven C Hunt; Elina Hypponen; Kevin B Jacobs; Marjo-Riitta Jarvelin; Pekka Jousilahti; Antti M Jula; Jaakko Kaprio; John J P Kastelein; Manfred Kayser; Frank Kee; Sirkka M Keinanen-Kiukaanniemi; Lambertus A Kiemeney; Jaspal S Kooner; Charles Kooperberg; Seppo Koskinen; Peter Kovacs; Aldi T Kraja; Meena Kumari; Johanna Kuusisto; Timo A Lakka; Claudia Langenberg; Loic Le Marchand; Terho Lehtimäki; Sara Lupoli; Pamela A F Madden; Satu Männistö; Paolo Manunta; André Marette; Tara C Matise; Barbara McKnight; Thomas Meitinger; Frans L Moll; Grant W Montgomery; Andrew D Morris; Andrew P Morris; Jeffrey C Murray; Mari Nelis; Claes Ohlsson; Albertine J Oldehinkel; Ken K Ong; Willem H Ouwehand; Gerard Pasterkamp; Annette Peters; Peter P Pramstaller; Jackie F Price; Lu Qi; Olli T Raitakari; Tuomo Rankinen; D C Rao; Treva K Rice; Marylyn Ritchie; Igor Rudan; Veikko Salomaa; Nilesh J Samani; Jouko Saramies; Mark A Sarzynski; Peter E H Schwarz; Sylvain Sebert; Peter Sever; Alan R Shuldiner; Juha Sinisalo; Valgerdur Steinthorsdottir; Ronald P Stolk; Jean-Claude Tardif; Anke Tönjes; Angelo Tremblay; Elena Tremoli; Jarmo Virtamo; Marie-Claude Vohl; Philippe Amouyel; Folkert W Asselbergs; Themistocles L Assimes; Murielle Bochud; Bernhard O Boehm; Eric Boerwinkle; Erwin P Bottinger; Claude Bouchard; Stéphane Cauchi; John C Chambers; Stephen J Chanock; Richard S Cooper; Paul I W de Bakker; George Dedoussis; Luigi Ferrucci; Paul W Franks; Philippe Froguel; Leif C Groop; Christopher A Haiman; Anders Hamsten; M Geoffrey Hayes; Jennie Hui; David J Hunter; Kristian Hveem; J Wouter Jukema; Robert C Kaplan; Mika Kivimaki; Diana Kuh; Markku Laakso; Yongmei Liu; Nicholas G Martin; Winfried März; Mads Melbye; Susanne Moebus; Patricia B Munroe; Inger Njølstad; Ben A Oostra; Colin N A Palmer; Nancy L Pedersen; Markus Perola; Louis Pérusse; Ulrike Peters; Joseph E Powell; Chris Power; Thomas Quertermous; Rainer Rauramaa; Eva Reinmaa; Paul M Ridker; Fernando Rivadeneira; Jerome I Rotter; Timo E Saaristo; Danish Saleheen; David Schlessinger; P Eline Slagboom; Harold Snieder; Tim D Spector; Konstantin Strauch; Michael Stumvoll; Jaakko Tuomilehto; Matti Uusitupa; Pim van der Harst; Henry Völzke; Mark Walker; Nicholas J Wareham; Hugh Watkins; H-Erich Wichmann; James F Wilson; Pieter Zanen; Panos Deloukas; Iris M Heid; Cecilia M Lindgren; Karen L Mohlke; Elizabeth K Speliotes; Unnur Thorsteinsdottir; Inês Barroso; Caroline S Fox; Kari E North; David P Strachan; Jacques S Beckmann; Sonja I Berndt; Michael Boehnke; Ingrid B Borecki; Mark I McCarthy; Andres Metspalu; Kari Stefansson; André G Uitterlinden; Cornelia M van Duijn; Lude Franke; Cristen J Willer; Alkes L Price; Guillaume Lettre; Ruth J F Loos; Michael N Weedon; Erik Ingelsson; Jeffrey R O'Connell; Goncalo R Abecasis; Daniel I Chasman; Michael E Goddard; Peter M Visscher; Joel N Hirschhorn; Timothy M Frayling
Journal:  Nat Genet       Date:  2014-10-05       Impact factor: 38.330

10.  IntOGen-mutations identifies cancer drivers across tumor types.

Authors:  Abel Gonzalez-Perez; Christian Perez-Llamas; Jordi Deu-Pons; David Tamborero; Michael P Schroeder; Alba Jene-Sanz; Alberto Santos; Nuria Lopez-Bigas
Journal:  Nat Methods       Date:  2013-09-15       Impact factor: 28.547

View more
  9 in total

1.  RGmatch: matching genomic regions to proximal genes in omics data integration.

Authors:  Pedro Furió-Tarí; Ana Conesa; Sonia Tarazona
Journal:  BMC Bioinformatics       Date:  2016-11-22       Impact factor: 3.169

2.  Transcription-factor-dependent enhancer transcription defines a gene regulatory network for cardiac rhythm.

Authors:  Xinan H Yang; Rangarajan D Nadadur; Catharina Re Hilvering; Valerio Bianchi; Michael Werner; Stefan R Mazurek; Margaret Gadek; Kaitlyn M Shen; Joseph Aaron Goldman; Leonid Tyan; Jenna Bekeny; Johnathon M Hall; Nutishia Lee; Carlos Perez-Cervantes; Ozanna Burnicka-Turek; Kenneth D Poss; Christopher R Weber; Wouter de Laat; Alexander J Ruthenburg; Ivan P Moskowitz
Journal:  Elife       Date:  2017-12-27       Impact factor: 8.140

3.  A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature).

Authors:  Xinan Holly Yang; Fangming Tang; Jisu Shin; John M Cunningham
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

4.  CisPi: a transcriptomic score for disclosing cis-acting disease-associated lincRNAs.

Authors:  Zhezhen Wang; John M Cunningham; Xinan H Yang
Journal:  Bioinformatics       Date:  2018-09-01       Impact factor: 6.937

5.  Transcriptomics and network analysis highlight potential pathways in the pathogenesis of pterygium.

Authors:  Juliana Albano de Guimarães; Bidossessi Wilfried Hounpke; Bruna Duarte; Ana Luiza Mylla Boso; Marina Gonçalves Monteiro Viturino; Letícia de Carvalho Baptista; Mônica Barbosa de Melo; Monica Alves
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

6.  Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.

Authors:  Xinan Holly Yang; Fangming Tang; Jisu Shin; John M Cunningham
Journal:  BMC Syst Biol       Date:  2017-10-03

Review 7.  High Throughput Sequencing for Detection of Foodborne Pathogens.

Authors:  Camilla Sekse; Arne Holst-Jensen; Ulrich Dobrindt; Gro S Johannessen; Weihua Li; Bjørn Spilsberg; Jianxin Shi
Journal:  Front Microbiol       Date:  2017-10-20       Impact factor: 5.640

8.  Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks.

Authors:  André F Rendeiro; Christian Schmidl; Jonathan C Strefford; Renata Walewska; Zadie Davis; Matthias Farlik; David Oscier; Christoph Bock
Journal:  Nat Commun       Date:  2016-06-27       Impact factor: 14.919

9.  Testing Proximity of Genomic Regions to Transcription Start Sites and Enhancers Complements Gene Set Enrichment Testing.

Authors:  Christopher Lee; Kai Wang; Tingting Qin; Maureen A Sartor
Journal:  Front Genet       Date:  2020-03-06       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.